Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Hemostemix Inc
V.HEM
Alternate Symbol(s):
HMTXF
Healthcare
Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP...
-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:HEM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(26)
•••
GustheGreek
X
View Profile
View Bullboard History
Comment by
GustheGreek
on Jan 19, 2023 7:21am
RE:Interest
Outlook for 2023 looks very promising. Hopefully the catalysts coming up will get this thing moving to where it should be, around a 250 million cap. 10-15X where it sits now. GLTA!!!
(120)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Post by
ENEMENEMYNEMO
on Jan 13, 2023 3:40pm
Interest
Nice to see some interest here, hopefully someone has heard some promising news.
Lahontan Gold Announces Filing of Santa Fe Technical Report
posted Nov 29, 2024 9:00am by
Lahontan Gold Corp.
-
|
Lahontan Gold is pleased to announce that the Company has filed on SEDAR+ an independent Technical Report and updated Mineral Resource Estimate ("MRE") titled "Santa Fe Project Technical Report," effective October 9, 2024, and dated November 27, 2024, for Lahontan's Santa Fe Mine gold and silver project, Santa Fe District, Mineral County, Nevada. ...read more
(3)
•••
PowerOfTheSun
X
View Profile
View Bullboard History
Post by
PowerOfTheSun
on Jan 07, 2023 9:34am
Thomas Smeenk provides an update on Hemostemix’s ACP-01 stem
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 08, 2022 2:35pm
New Press Release - Hemostemix Issued 'Your Fountain of Youth' Trademark by Cyprus
Calgary, Alberta--(Newsfile Corp. - December 8, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Office of the Registrar of Trademarks, Republic of Cyprus, issued Kwalata Trading Limited, a wholly owned subsidiary of...
read article.
(120)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Post by
ENEMENEMYNEMO
on Dec 05, 2022 5:46pm
Faster
.
(120)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Post by
ENEMENEMYNEMO
on Dec 05, 2022 5:45pm
Volume
Biggest volume in a long time! Is the ship sinking???
(2)
•••
CameronCole
X
View Profile
View Bullboard History
Post by
CameronCole
on Nov 30, 2022 10:11am
Exclusive Video Interview with Hemostemix Inc. and prior ACP
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 17, 2022 8:30am
New Press Release - Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview
Calgary, Alberta--(Newsfile Corp. - November 17, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to thank six-time Grammy Award Winner, Mr. Howie Lindeman, for his ACP-01 testimonial interview (https://www.youtube.com/watch?v=KTuq3Oy7WU0...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 15, 2022 8:44am
New Press Release - Hemostemix Announces Advancements in Its Automation of Production
Calgary, Alberta--(Newsfile Corp. - November 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the continued evolution of its patented Automated Cell Therapy System (ACTS). The Hemostemix ACTS is designed to scale our...
read article.
(2)
•••
CameronCole
X
View Profile
View Bullboard History
Comment by
CameronCole
on Nov 14, 2022 12:15am
RE:Emerging growth conference - Worth watching
Live Hemostemix interview this week! case studies from 2006 ACP-01 procedures
(2)
•••
CameronCole
X
View Profile
View Bullboard History
Post by
CameronCole
on Nov 14, 2022 12:14am
Hemostemix Interview this week!
Live interviews this week with Hemostemix patients!
(4)
•••
JocetooBad
X
View Profile
View Bullboard History
Post by
JocetooBad
on Oct 27, 2022 1:13pm
Emerging growth conference - Worth watching
https://youtu.be/yw4fBi7laLc
(4)
•••
JocetooBad
X
View Profile
View Bullboard History
Post by
JocetooBad
on Oct 26, 2022 1:40pm
Press release today re: clinical trials = serious business
Next studies will be well designed and will lead to real financing opportunities for HEM. I find this really interesting. GLTA
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 26, 2022 10:40am
New Press Release - Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials
Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Medicine and Clinical Trials. Dr. Giannetti and Dr...
read article.
(4)
•••
JocetooBad
X
View Profile
View Bullboard History
Post by
JocetooBad
on Oct 25, 2022 2:49pm
T. Smeenk bought 20k shares ($3000) yesterday
Better than nothing. It would be nice if other insiders also did that (or more).
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >